Cholesterol after CABG

New York, July 5, 2000 (Praxis Press) Studies show that a reduction in risk factors following coronary artery bypass surgery (CABG) improves patients' prognosis. Such patient management was suboptimal in Britain before the publication of landmark trials demonstrating the benefit of cholesterol reduction. In a 10-year audit of secondary prevention in CABG patients, Irving et al show that despite significantly improved management of well-established risk factors, including cholesterol concentratio

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

New York, July 5, 2000 (Praxis Press) Studies show that a reduction in risk factors following coronary artery bypass surgery (CABG) improves patients' prognosis. Such patient management was suboptimal in Britain before the publication of landmark trials demonstrating the benefit of cholesterol reduction. In a 10-year audit of secondary prevention in CABG patients, Irving et al show that despite significantly improved management of well-established risk factors, including cholesterol concentration, 48% of patients are not receiving appropriate cholesterol-lowering treatment (see paper). Patients who underwent a bypass surgery before 1994 are the least likely to receive a cholesterol-management program. It is important to note, though, that the study does not include data on patient compliance. These findings suggest that secondary prevention in CABG patients should stress cholesterol-management programs.

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Logo

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas

Sino Biological Logo

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech Logo

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform